Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
GO:190547516 | Oral cavity | OSCC | regulation of protein localization to membrane | 105/7305 | 175/18723 | 1.42e-08 | 2.85e-07 | 105 |
GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
GO:190179620 | Oral cavity | OSCC | regulation of signal transduction by p53 class mediator | 62/7305 | 93/18723 | 5.99e-08 | 1.09e-06 | 62 |
GO:003295620 | Oral cavity | OSCC | regulation of actin cytoskeleton organization | 189/7305 | 358/18723 | 6.81e-08 | 1.21e-06 | 189 |
GO:011005320 | Oral cavity | OSCC | regulation of actin filament organization | 150/7305 | 278/18723 | 2.68e-07 | 4.15e-06 | 150 |
GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
GO:003286916 | Oral cavity | OSCC | cellular response to insulin stimulus | 114/7305 | 203/18723 | 5.07e-07 | 7.41e-06 | 114 |
GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
GO:00434054 | Oral cavity | OSCC | regulation of MAP kinase activity | 101/7305 | 177/18723 | 8.13e-07 | 1.12e-05 | 101 |
GO:00070204 | Oral cavity | OSCC | microtubule nucleation | 28/7305 | 35/18723 | 8.71e-07 | 1.19e-05 | 28 |
GO:00182098 | Oral cavity | OSCC | peptidyl-serine modification | 175/7305 | 338/18723 | 1.09e-06 | 1.46e-05 | 175 |
GO:007137510 | Oral cavity | OSCC | cellular response to peptide hormone stimulus | 153/7305 | 290/18723 | 1.23e-06 | 1.63e-05 | 153 |
GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
GO:00467779 | Oral cavity | OSCC | protein autophosphorylation | 123/7305 | 227/18723 | 2.31e-06 | 2.93e-05 | 123 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK1 | SNV | Missense_Mutation | | c.184N>A | p.Asp62Asn | p.D62N | Q13153 | protein_coding | tolerated(0.38) | benign(0.033) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PAK1 | SNV | Missense_Mutation | | c.1114G>A | p.Glu372Lys | p.E372K | Q13153 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PAK1 | SNV | Missense_Mutation | | c.229N>A | p.Leu77Ile | p.L77I | Q13153 | protein_coding | tolerated(0.41) | benign(0.236) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1593N>C | p.Met531Ile | p.M531I | Q13153 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
PAK1 | SNV | Missense_Mutation | | c.113N>G | p.Ser38Cys | p.S38C | Q13153 | protein_coding | tolerated(0.17) | probably_damaging(0.917) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | insertion | Nonsense_Mutation | novel | c.226_227insGTGCACATGTATATATATGTATGCAAGAATTTTAATTTT | p.Ile75_Ser76insCysAlaHisValTyrIleCysMetGlnGluPheTerPhe | p.I75_S76insCAHVYICMQEF*F | Q13153 | protein_coding | | | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1532C>T | p.Ser511Leu | p.S511L | Q13153 | protein_coding | deleterious(0) | benign(0.135) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.946A>G | p.Ile316Val | p.I316V | Q13153 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.80N>A | p.Gly27Asp | p.G27D | Q13153 | protein_coding | deleterious_low_confidence(0.04) | benign(0.02) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | | c.95N>A | p.Gly32Glu | p.G32E | Q13153 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AZD-1152-HQPA | AZD-1152-HQPA | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TOZASERTIB | TOZASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | MLN-8054 | MLN-8054 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565861 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | RG-1530 | RG-1530 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |